AAAsieh Aref

Asieh Aref

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asieh Aref has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the Mortality Risk Factors Among COVID-19 Patients with Diabetes Mellitus

    by Mandana Pouladzadeh, Mehrnoosh Zakerkish, Homeira Rashidi, Armaghan Moravej Aleali, Asieh Aref, Seyed Mahmoud Latifi, Saghar Babadi, Atena Golabi, Zahra Ababzadeh, Fereshte Amini

    Background: Management of Coronavirus disease 2019 (COVID-19) patients with underlying disorders is a challenging issue at any time. Objectives: The present survey investigated the mortality rate of COVID-19 patients with various underlying disorders. Methods: In the present cross-sectional study, patients with COVID-19 who were referred to the Razi Hospital in Ahvaz from Feb 2020 to Oct 2020 were evaluated. Non-probability sampling method was used for sample collection. All documented information, including length of hospitalization, comorbidities, survival, and clinical and laboratory findings, were collected. Results: In the present study, 500 diabetic patients with COVID-19 infection were included. The mean age of participants was 59.61 ± 14.88 years old. Of the subjects, 192 (38.4%) were female and 308 (61.6%) were male. DM solely was the most frequent underlying disorder (46.2%), followed by co-occurrence of DM and hypertension (HTN) (43%). The mortality rate was 15% and was more frequent in patients with simultaneous DM and HTN (66%) (P-value < 0.001). Also, the mortality rate was significantly higher in males than females (72% vs 28%) (P-value = 0.042). Further analysis indicated that the mean of white blood cells (WBC), neutrophil count, blood urea nitrogen, glucose, creatinine, and aspartate aminotransferase were significantly higher in expired patients (P-value < 0.05). Post Hoc analysis showed the highest pulse rate (PR) and respiratory rate (RR) in patients with DM, HTN, and chronic obstructive pulmonary disease (COPD) (P-value < 0.001). Conclusions: The present investigation showed that comorbidities significantly increase the COVID-19 mortality rate. Our findings revealed that more attention is required for COVID-19 patients with HTN and DM. Due to discrepancies with recent investigations, further studies with more follow-up are recommended.


  • Open Access

    Acute Renal Failure in a Patient with Coronavirus: A Case Report of a Rarely-Seen Presentation

    by Asieh Aref, Zohre Valizadeh, Mohammad Sakiani, Mohsen Maleknia, Zahra Shahpouri Arani, Hashem Kazemi

    Introduction: Coronavirus disease (COVID-19) presents primarily as an acute respiratory disorder with interstitial and vesicular pneumonia but affects various organs, including the kidneys, heart, gastrointestinal tract, blood, and gastric nervous system. This study aimed to report a case of COVID-19 with acute kidney injury (AKI). Case Presentation: A 37-year-old female patient with two positive COVID PCR and Cr = 0.8 but with no record of AKI was admitted to Razi Hospital in Ahvaz in April 2020 for ten days. After completion of the informed consent, her blood samples were obtained, and a renal biopsy and other tests were performed on her. Conclusions: Announced COVID-19 cases reported in AKI. In sum, patients with a high prevalence of comorbidities, such as AKI, suffered from severe COVID-19. Therefore, it was recommended that the risk of acute kidney damage, in addition to the respiratory failure risk, should be taken into consideration in patients with COVID-19. Furthermore, COVID-19 may have presented symptoms of AKI in patients with no history.

  • Open Access

    The effect of single dose prophylactic vancomycin before semi-permanent catheterization to prevent catheter related infection; a randomized controlled trial, phase II

    by Asieh Aref, Zohreh Zandbaf, Ali Ghorbani, Shahla Ahmadi Halili

    Introduction: Catheter-related infections are a common complication and a major cause of morbidity and mortality in hemodialysis patients with tunneled central venous catheters. The optimal strategy for the management and prevention of catheter-related infections is unclear. Objectives: This study is aimed to evaluate the single-dose prophylactic vancomycin efficacy before semi-permanent catheterization to prevent catheter-related infection. Patients and Methods: This randomized double-blind controlled clinical trial was conducted on patients with chronic renal failure requiring hemodialysis and insertion of a double-lumen central venous catheter admitted to Ahvaz Golestan Hospital. The intervention group (n=30) received 1 g of vancomycin intravenously one hour before catheter insertion and the control group (n=30) received an equal amount of normal saline. The incidence of catheter-related infections and other complications for 6 months was evaluated. Results: During the 6-month follow-up, hospitalization due to catheter-related infection and the need for antibiotic administration was observed in 9 patients (30.0%) who received vancomycin and 14 patients (46.7%) in the control group (P=0.184). Catheter extraction due to infection was observed in 4 patients of the vancomycin group (13.3%) and 6 patients of the control group (20.7%) (P=0.451). Complications other than infection were observed in four patients (13.3%) in each group (P=1.000). The mean time to onset of infection was 2.43 ±0.38 months in the control group and 3.85 ± 0.42 months in the vancomycin group (P=0.002). Conclusion: Although a single dose of intravenous vancomycin one hour before insertion of a bi-luminal hemodialysis catheter did not show a significant effect on preventing catheter-related infections over 6 months, it significantly delayed the onset of infection. Trial Registration: The trial protocol was approved by Iranian Registry of Clinical Trial (Ethical code: IR.AJUMS.HGOLESTAN.REC.1399.106 and IRCT code: IRCT20201206049617N1; https://www.irct.ir/trial/52832).


  • Open Access

    Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate

    by Asieh Aref, Samaneh Tirom, Heshmatollah Shahbazian, Ali Ghorbani

    Introduction: Based on the evidence, rituximab may be an effective treatment for kidney transplantation for reducing panel-reactive antibody. Objectives: This study was conducted to investigate the effect of rituximab on reducing the panel in transplant dialysis patients. Patients and Methods: This is an interventional study that was conducted on 20 dialysis patients who were candidates for kidney transplantation. Patients first had a panel-reactive antibody test and patients with a panel-reactive antibody above the age of 30 were included in the study. First, rituximab was administered at a dose of one gram and then after two weeks, another dose of one gram was administered. Panel-reactive antibody was measured baseline, one and six months later. Results: One and six months after stopping the drug, we found a significant decrease in the mean amount of reactive antibodies. Additionally, six months after stopping the drug, a significant decrease in the level of patients’ reactive antibodies in comparison to one month before taking the drug was detected (P<0.05). Conclusion: The findings showed that treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients. However, more studies are needed to optimize rituximab injection protocols.

  • Open Access

    Lessons from monitoring, screening, evaluation and early detection of breast cancer in Iran

    by Ali Ehsanpour, Amir Mohammad Papan, Shirin Kianpour, Pedram Nazari, Asieh Aref, Parastoo Ahangpour

    Lessons from monitoring, screening, evaluation and early detection of breast cancer in Iran


  • Open Access

    Incidence of acute kidney injury in bone marrow transplant patients; investigation of consequences within one to three years

    by Asieh Aref, Mohsen Maleknia, Alireza Nasrollahi, Abbas Hajifathali, Mahshid Mehdizadeh, Hashem Kazemi, Mohammad Hassan Ghadiani

    Introduction: Previous studies have demonstrated that acute kidney injury (AKI) is a serious complication following hematopoietic stem cell transplantation (HSCT). The incidence of AKI in association with HSCT varies considerably because of several definitions for AKI. Objectives: In this study, we determined the rate of AKI after bone marrow transplantation (BMT) and its effects on patients’ outcomes according to modern definitions of AKI to conclude whether all these criteria can be useful for predicting AKI occurrence after BMT or not. Patients and Methods: We conducted a retrospective study of 271 patients undergoing HSCT, and after obtaining written informed consent from all patients, the required information was reviewed. AKI was defined according to RIFLE, KDIGO, and AKIN criteria. Renal function was assessed by calculating creatinine clearance, urine output, and estimated glomerular filtration rate (eGFR), determined through the MDRD equation. Results: Allogeneic and autologous transplantations were performed on 38 (14.02%) and 233 (85.97%) patients, respectively. According to the RIFLE criteria, 96 patients (35.42%) suffered from AKI, and based on AKIN, and KDIGO criteria, 101 patients (37.26%) were afflicted with it after BMT. The one-year mortality rate in allogeneic transplant patients with a history of AKI was 30.43% and 53.33% in patients without a history of AKI. The three-year mortality rate in allogeneic transplant patients with and without a history of AKI was 52.17% and 73.33% respectively, which showed no statistically significant difference. The three-year mortality rate in autologous transplant patients with and without a history of AKI was 60.27% and 22.5%, respectively. Conclusion: The one-year and three-year mortality rates, survival of patients, and AKI’s diagnosis were similar in all three criteria. Therefore, all these criteria can be useful for the prediction of AKI occurrence after BMT.


  • Open Access

    In-center hemodialysis and COVID 19 infection

    by Seyed Seifollah Beladi Mousavi, Shahla Ahmadi Halili, Asieh Aref

    • 1 September 2011
      • Vol. 5  (5) , 342-6

    Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients.

    by Ali Ghorbani, Heshmatollah Shahbazian, Ali Ehsanpour, Asieh Aref

    Both atorvastatin and mycophenolate mofetil (MMF) have been used for panel reactive antibodies (PRA) reduction in transplant candidates. The purpose of this study was to compare the effect of low-dose MMF and atorvastatin on PRA in sensitized hemodialysis patients waiting for kidney transplantation. A total of 40 adult patients with end-stage renal disease who were highly sensitized to human leukocyte antigens (PRA > 40%) were enrolled and randomly assigned into atorvastatin or low-dose MMF groups. All of the patients received the treatments for 2 months. The PRA status was determined at the end of the 1st and 2nd month. Forty percent of the patients in the atorvastatin group compared with 5% in the low-dose MMF group showed complete response, defined as a minimum 50% reduction in PRA (P = .02). Reduction of PRA in the atorvastatin group was significantly higher than that in the low-dose MMF group (P = .01). No major infectious or other complications occurred in our patients. Atorvastatin has a significant effect on lowering of PRA in sensitized hemodialysis patients waiting for kidney transplantation. In addition, a short course of low-dose MMF is safe in ESRD patients; however, it has no effect on reduction of PRA.

  • Open Access

    Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients

    by A Ehsanpour, A Ghorbani, M Aalamshah, H Shahbazian, A Aref

    The optimal vascular access for chronic maintenance hemodialysis is the arteriovenous fistula (AVF). Several studies suggest a role for antiplatelet agents in the prevention of primary AVF failure. A double-blind, randomized trial was conducted to assess the efficacy and safety of clopidogrel in hemodialysis patients. Ninety three patients were randomized to receive 75 mg/daily of clopidogrel or placebo. The treatment was initiated 7-10 days prior to scheduled access surgery and continued up to six weeks postoperatively, and then patients were monitored for six months. The primary outcome was AVF failure eight weeks after fistula creation. With a permuted block randomization schedule, 46 patients received clopidogrel and 47 patients received control placebo. The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group ( P = 0.03). The hazard ratio for the incidence of primary AVF failure was 0.72 (CI 95%, 0.41-1.01). Analysis of covariables indicated that this effect occurred principally as a result of clopidogrel administration. First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group ( P = 0.008). No life-threatening adverse event or severe bleeding was recorded in both groups. Clopidogrel seems to be effective and safe for prevention of primary AVF failure in hemodialysis patients.